Needham Reiterates Buy on Autolus Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum reiterates a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and maintains a $7 price target.
June 02, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum reiterates a Buy rating on Autolus Therapeutics and maintains a $7 price target.
The news directly mentions Autolus Therapeutics (NASDAQ:AUTL) and the Buy rating reiterated by Needham analyst Gil Blum. This reaffirmation of a positive rating and the maintained price target of $7 could lead to a short-term positive impact on the stock price, as it signals confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100